Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 3 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
The quote below is from wikipedia (afoaf's cat won't pretend he did the research himself)
The full name is; 3-[2-(2-methoxybenzylamino)ethyl]-1H-quinazoline-2,4-dione or simply RH-34!
Is it a psychedelic? Anti-psychoatic? Phenethylamine? amphetamine? Active at all? F@#k knows.. seems to be the answer at the moment. It was offered to afoaf's cat just recently. At first it sounded like another obscure and sickening cannabinoid but further research gave the information below.
"RH-34 is a compound which acts as a potent and selective partial agonist for the 5-HT2A serotonin receptor subtype. It was derived by structural modification of the selective 5-HT2A antagonist ketanserin , with the 4-(p-fluorobenzoyl)piperidine moiety replaced by the N-(2-methoxybenzyl) pharmacophore found in such potent 5-HT2A agonists as NBOMe-2C-B and nbomE-2c-I. This alteration was found to retain 5-HT2A affinity and selectivity, but reversed activity from an antagonist to a moderate efficacy partial agonist."
Other forums have just started to discuss this chem, there are no trip reports yet. This cat is not asking anyone to be the first but he is interested to hear if anyone has.
No one can seem to agree what the effects will actually be.....what do you guys and dolls think?
Mol. mass325.361 g/mol
Related Compounds with Annotation (listed just in case another pops up on the market) : 3-(4-methoxybenzyl)-N-(3-(2-piperidin-1-yl)ethyl)-2,4-dioxoquinazoline-7-carboxamide ,SureCN8230064, SGB1534,5-MeO-NBpBrT ,Ketanserin
SureCN10321390 - Compound Summary (CID 10041987)
Also known as: 3-[2-[[(2-Methoxyphenyl)methyl]amino]ethyl]-2,4(1H,3H)-quinazolinedione, 1028307-48-3
Molecular Formula: C18H19N3O3
Molecular Weight: 325.36176
Study on quinazolinedione 5htpxxx mapping and Binding
Quinazoline is a compound made up of two fused six-membered simple aromatic rings, a benzene ring and a pyrimidine ring. Its chemical formula is C8H6N2. Quinazoline is yellow and crystalline. Any derivative of quinazoline may be described as a quinazoline compound.
Medicinally it has been used in various areas especially as an anti-malarial agent and in cancer treatment. One example of a compound containing the quinazoline structure is doxazosin mesylate.
RH-34 is a compound which acts as a potent and selective partial agonist for the 5-HT2A serotonin receptor subtype. It was derived by structural modification of the selective 5-HT2A antagonist ketanserin, with the 4-(p-fluorobenzoyl)piperidine moiety replaced by the N-(2-methoxybenzyl) pharmacophore found in such potent 5-HT2A agonists as NBOMe-2C-B and NBOMe-2C-I. This alteration was found to retain 5-HT2A affinity and selectivity, but reversed activity from an antagonist to a moderate efficacy partial agonist
The 5-HT2A receptor (5-HT2AR) is a biogenic amine receptor that belongs to the class A of G protein coupled receptors. It is characterized by a low affinity for serotonin (5-HT) and for other primary amines. Introduction of an ortho-methoxybenzyl substituent at the amine nitrogen increases the partial agonistic activity by a factor of 40 to 1400 compared with 5-HT.
The present study was to analyse the QSAR of a series of 51 5-HT2AR partial agonistic arylethylamines, tested in vascular in-vitro assays on rats, at a structure-based level and to suggest ligand binding sites. The compounds belong to three different structural classes, (1) indoles, (2) methoxybenzenes and (3) quinazolinediones. Following a hierarchical strategy, different methods have been applied which all contribute to the investigation of ligand-receptor interactions: fragment regression analysis (FRA), receptor modeling, docking studies and 3D QSAR approaches (comparative molecular field analysis, CoMFA, and comparative molecular similarity index analysis, CoMSIA).
An initial FRA indicated that methoxy substituents at indole and phenyl derivatives increase the activity and may be involved in polar interactions with the 5-HT2AR. The large contribution of lipophilic substituents in p position of phenethylamines suggests fit to a specific hydrophobic pocket. Secondary benzylamines are more than one order of magnitude more active than their NH2 analogs. An ortho-OH or -OMe substituent at the benzyl moiety further increases activity.
Homology models of the human and rat 5-HT2AR were generated using the crystal structure of bovine rhodopsin and of the beta2-adrenoceptor as templates. The derivation of the putative binding sites for the arylethylamines was based on the results from FRA and on mutagenesis data. Both templates led to 5-HT2AR models with similar topology of the binding pocket within the transmembrane domains TM3, TM5, TM6 and TM7. Docking studies with representative members of the three structural classes suggested that the aryl moieties and particularly para-substituents in phenyl derivatives fit into a hydrophobic pocket formed by Phe2435.47, Phe2445.48 and Phe3406.52. The 5-methoxy substituents in indole and phenyl compounds form H bonds with Ser2395.43. In each case, an additional H bond with Ser1593.36 may be assumed. The cationic amine interacts with the conserved Asp1553.32. The benzyl group of secondary arylethylamines is inserted into another hydrophobic pocket formed by Phe3396.51, Trp3677.40 and Tyr3707.43. In this region, the docking poses depend on the template used for model generation, leading to different interactions especially of ortho- substituents.
The docking studies with the beta2-adrenoceptor based rat 5-HT2AR model provided templates for a structure-based alignment of the whole series which was used in 3D QSAR analyses of the partial agonistic activity. Both approaches, CoMFA and CoMSIA, led to highly predictive models with low complexity (cross-validated q2 of 0.72 and 0.81 at 4 and 3 components, respectively). The results were largely compatible with the binding site and confirm the docking studies and the suggested ligand-receptor interactions. Steric and hydrophobic field effects on the potency indicate a hydrophobic pocket around the aryl moiety and near the para position of phenyl derivatives and account for the increased activity of secondary benzylamines. The effects of electrostatic and H-bond acceptor fields suggest a favourable influence of negative charges around the aryl moiety, corresponding to the increase in potency caused by methoxy substituents in 2-, 4-, 5- and 6-position of phenethylamines and by the quinazolinedione oxygens. This is in accord with the role of Ser1593.36 and Ser2395.43 as H bond donors. At the benzyl moiety, the negative charge and the acceptor potential of 2-hydroxy and -methoxy substituents is of advantage.
Agonists stabilize or induce active receptor states not reflected by the existing crystal structures. Based on models of different rhodopsin states, a homology modeling and ligand docking study on corresponding 5-HT2AR states suggested to be specific to agonist and partial agonist binding, respectively, was performed. The models indicate collective conformational changes of TM domains during activation. The different 5-HT2AR states are similar with respect to the amino acids interacting with the arylethylamines, but show individual topologies of the binding sites. The interconversion of states by TM movements may be accompanied by co-translations and rotations of the ligands. In the case of the secondary amines considered, the tight fit of the benzyl substituent into a hydrophobic pocket containing key residues in TM6 probably impedes the complete receptor activation due to inhibiting the rotation of this helix. High affinity of a partial agonist is therefore often at the expense of its ability to fully activate a receptor.
* there are a lot of Quinazolinediones in this study.. I will list at the bottom and attach the PDF.. its a book btw
188.8.131.52 Quinazolinediones – a new partial agonistic structure
A relatively new class of agonists identified in SAR studies focused on analogs of the 5-HT2A receptor antagonist ketanserin is represented by quinazolinedione derivatives. EZS-8, quasi the quinazolinedioneethylamine moiety of ketanserin, unexpectedly displayed partial 5-HT2AR agonistic activity. Further studies on this new chemical class led to the new potent partial agonist RH-34 (Figure 1.15).
Surveying the different classes of arylalkylamines described above (including ergolines as cyclisized derivatives), it is possible to define three general requirements for optimal partial 5-HT2AR agonistic activity: 1. An amino nitrogen (protonated at pH 7), separated from the aromatic ring by two carbon atoms. 2. Presence of two electron donors (or acceptors) in the aryl moiety. 3. A hydrophobic substituent at the aryl moiety increases affinity and activity.
By introduction of larger substituents at the amine nitrogen it is possible to gain partial agonists that are up to 400-1400 times more active than 5-HT due to higher affinity. This "affinity-conferring" principle may be applied to other structural classes as indoles and quinazolinediones. To obtain still more potent 5-HT2AR agonists and to investigate structure-activity relationships (SAR), a series of more than 60 compounds was synthesized and tested for 5-HT2AR agonistic potency (pEC50) and intrinsic activity (Emax) on rat arteries (Elz et al., 2002; Heim et al., 1998; Heim et al., 2002; Pertz et al., 2000; Ratzeburg et al., 2003). The series comprises diverse primary and secondary arylethylamines belonging to different structural classes (mainly indoles, methoxybenzenes and quinazolinediones), and shows a high variability of pEC50 from 4 to 10 and of Emax (intrinsic activity compared to 5-HT) from 15 to 70%. The QSAR of the compounds were analyzed following a hierarchical strategy with successive application of different methods: fragment regression analysis (FRA), receptor modeling, docking studies, and 3D-QSAR approaches. Generally, all these methods contribute to the investigation of ligand-receptor interactions.
In this study, the bioactive conformations and the binding modes of three different structural classes of 5-HT2AR partial agonistic arylethylamines – (1) indoles, (2) methoxybenzenes, (3) quinazolinediones – were derived. Rat and human 5-HT2AR models were generated using the X-ray structure of bovine rhodopsin as template. Results from in vitro mutagenesis experiments contributed to the identification of important binding site amino acids. Three compounds representing the structural classes could be docked at this site in a consistent mode, resulting in a structure- based alignment which may serve as starting point for 3D QSAR analysis. The question is whether new 5-HT2AR models based on the recent crystal structures of the human β2 adrenoceptor will confirm the binding models derived so far.
The 5-HT2AR agonistic activity of mostly less potent primary amines as 5-HT, 3-(2-aminoethyl)quinazoline-2,4-dione, mescaline, and 1-(4-bromo-2,5-dimeth- oxyphenyl)-isopropylamine (DOB) (Figure 5.1) was increased by a factor of 50 to 2000 (Elz et al., 2002; Heim et al., 1998; Pertz et al., 2000). The most interesting derivatives showing partial agonistic activity were obtained by introduction of an ortho-methoxybenzyl substituent at the amine nitrogen and are up to 400-1400 times more potent than 5-HT.
In accord with the general analogy of the binding sites (see Figure 5.8), the important interactions of the three compounds with the β2AR based r5-HT2AR model are similar to those suggested from the receptor model derived from bovine rhodopsin (for detailed discussion, see Chapter 4), and can be summarized as follows: - The arylethylamine moieties interact with three sites: (1) Asp1553.32 forming a salt bridge with the cationic amine, (2) a hydrophobic pocket comprising Phe2435.47, Phe2445.48 and Phe3406.52, as well as (3) Ser1593.36 and Ser2395.43 as possible H bond acceptors or donors. - Strongly potency increasing halogen substituents in para-position of dimethoxy- phenyl compounds (cpd 231, Figure 5.9 B) and the phenyl moiety of quinazolinedione derivates (cpd.169, Figure 5.9 C) project onto the hydrophobic pocket formed by Phe2435.47 and Phe2445.48. - Ser1593.36 may interact with the indole NH, one of the the quinazolinedione oxygens and with the 2-OMe group of dimethoxyphenyl compounds. In the h5- HT2AR, Ala2425.46 of the rat species is mutated into Ser2425.46 which is possibly involved in H bonds with these groups, too.
5-OH and 5-OMe substituted indoles and 2,5-dimethoxyphenethyl compounds are able to form H bonds with Ser2395.43. Thus, bidentate polar interactions of aryl moieties are possible in the case of these derivatives, whereas quinazolinediones probably form only one H bond. - The benzyl substituent (RN) interacts with a second hydrophobic pocket consisting of aromatic residues around Phe3396.51 (Trp3677.40 and Tyr3707.43). - Since an oxygen in ortho-position of the benzyl group (2-OH, 2-OMe) further enhances activity, an additional interaction with a hydrogen donor, possibly via water, may be suggested. In contrast to the models based on rhodopsin, Asn3436.55 is too far away from these substituents for direct interaction.
I don't know.. just download the PDF and read it
^ Maria Silva PhD. Theoretical study of the interaction of agonists with the 5-HT2A receptor. Universität Regensburg, 2009.
Depositor: Thomson PharmaExternal ID: 00552313 (can't get into this one to read it)
Potential Modes of Interaction of 9-Aminomethyl-9,10-dihydroanthracene (AMDA) Derivatives with the 5-HT2A Receptor: A Ligand Structure-Affinity Relationship, Receptor Mutagenesis and Receptor Modeling Investigation
When something is this confusing and clearly untested, it's best avoided. Why risk it? These "labs" in china are just producing anything they can and seeing id anyone will buy it, they aren't offering drugs, they are just doing lists of chemicals.
I recently discussed this compound with a few associates and the consensus was that it was potentially dangerous. The chemical that it was developed from, known as ketanserin, possesses antagonist activity at a wide range of other receptor sites, such as the α1 andrenergic and H1 histamine receptors. If the addition of the NBOMe pharmacophore produced a change from antagonist to agonist at 5-HT2, it's possible that it had a similar effect on it's affinity for these other receptors as well, although a greater study of the compound's SAR to be sure. A strong affinity for these sites could have all sorts of bizarre and unwanted effects.
It's possible that there may be a psychedelic response from this compound. It's also possible that it could have potentially horrendous side effects. I would recommend extreme caution to be exercised if anyone decides to bioassay this compound. Normally I wouldn't recommend it, but I think animal testing might be appropriate in this case. Another option would be to try graduated micro-doses while watching for any sort of adverse reaction, but I really think that at least a few rodent trials are in order. From everything I could find in journals it has only ever been tested in vitro, so tread lightly.
I was searching the net, hoping to find any updates on this chemical. There was little information apart from some speculations and contradicting reports on doses (500mcg for a nice trip versus 2mg for no effects), but i've found a trip-report in one of the russian forums.
It was written by a member with 800+ posts and 1000 reputation, so i think it's not a scam or vendors promoting the product, although the report is somehow sketchy, and there's no info on dose, so take it with a pinch of salt.
So, with help of my little Russian knowledge, google translate and my friend, who knows russian better than me, but was busy and helped me only with the hardest parts, here it is. There were some curses that expressed the emotions strongly and entertained me, so i tried to keep close to original and used these words (providing explanation of what do they mean).
I snorted it yesterday, here's my trip.
Exactly at 22.00 I snorted contents of the first sample (although I was warned to take half of it). I have to say, it didn't taste very well. About hour later i still thought, what's going on in my nose, why it hurts so much?
About 10-15 minutes later I feel that it's no joke. This thing works, and pizdets*, it works strong. I simply lied on the side, watched the window and ohueval**, simply ohueval (the vision got blurry, he couldn't see hands before him, they morphed into something, shit knows what, i don't know how to describe it). Decided to turn on TV but that's not the point. There were such things happening in it that a question, "what the fuck is going on", didn't give me peace, and I tried to answer it, without knowing nahui*** i got that question at the first place? Then i turned on the computer, but as soon as it finished loading, i turned it off (remembered what happened with TV).
Then, after hour i went to the balcony. I live in one of upper floors, and in such place, where from balcony i can see whole city. I simply ohuel**, looking at what was happening outside. It seemed that city is alive, every house, every yard, everything was shining, shimmering and intertwining with each other extremely beautifully. I stood next half an hour just stupidly admiring the view of the city.
Then (I don't remember exactly how it happened) something happened to me. I wanted to lay down and went to bed, lied down, but couldn't find a place, constantly moving, turning and tossing all the time. But in the end i felt better and after fifteen minutes I again stood up and went to balcony. Two hours after snorting my condition and health improved and i understood that the effects are fading, sadly. After four hours and a meal i felt sober and everything was gone. So, the conclusion:
1) strenght is 10 out of 10
2) duration is 8 out of 0
3) the big advantage is that it doesn't affect the eyes. Pupils look like you were sober.
4) the substance is worth it, take it and don't regret it****
5) and almost forgot, there's little comedown/after effects. Just light tremor every ten minutes, and it continued till 6 am. I hadn't fall asleep till now.
The guy was later asked for the dose, but he replied that he really has no idea and didn't provide the guess.
These can't be translated: *Take a word "pussy". Make extremely strong interjection (word used to express feelings/emotion) out of it. This new word could be used for positive and negative things alike. It's strong emotion.
**Take the word "dick". Then make a verb out of it, which would express extreme positive amazement mixed with happiness.
***Literally "on dick". In this case it's used to question the purpose of something instead of "why".
****We don't know if it really was RH-34, we don't know the dose, so do not take this advice lightly
I also think that this topic should be renamed to: RH-34 (3-[2-(2-methoxybenzylamino)ethyl]-1H-quinazoline-2,4-dione) drug info
It is probably somewhat active as a psychedelic, but as mentioned, side-effects are as of yet unknown. Since this russian report was by snorting, it may be broken down by stomache metabolism and might work only via faster ROA, like snorting or injecting (but please do not try that as a first ROA).
There's a guy on another forum, named cr00k, who took a series of experiments with this substance. As it's one of very few sources of information, i'm posting a summary of his experiments. He used the substance cut with creatine, with proportions 10% of RH-34 and 90% of creatine. Guy also is on quietapine, but he stopped using it 3 days prior trials, and 3 days before that used much smaller dose than recommended (10mg a day).
Anw., the trials:
1st try: 27 mg orally, tooked in two doses, separated in hour. A bit increased mood, pleasant excitement, but could be placebo or just threshold effects. No psychedelic effects.
2nd try: 10 mg insufflated, then 50 mg insufflated six hours later. Disgusting taste, still baseline after 105 mins after second insufflation. No further effects reported.
3rd try: 400mg mixed with 25% propylene glycol, 25% etanol and water, no effects experienced.
4th try: 200 mg insufflated + some 70% ethanol to help absorption. More saliva, subtle tension around the jaw, maybe threshold effects, "fucking nothing" at +128 mins.
He then added water to substance, filtering out hardly soluble creatine. From rest of his 3250 mgs of substance he got 444 mgs. He hopes the substance is around 75% pure now.
4th try continued: insufflated 40mg at +174 mins. Maybe slight serotonergic action, cigaretes tastes crappy, as they'd do when he'd was on SSRI.
5th try: 40 mg rectally. No effects, then after 20 mins, 100mg rectally again. Some stimulation, which doesn't seem comfortable.
And then the guy has finished his trials. So although there could be some impact of his medication, overall the things doesn't very promising. So, interesting to see such conflicting reports - there could be that the russian guy from the previous post had got something entirely different, as cr00k claims to have gottenhis sample directly from the vendor.
What have me wondering, is that such substance is sold cut to 10%.
Id be weary of any product that the vendor admits to using heavy cuts.. i mean he says creatine, but who knows. It compounds the questionability of the product by 4.
1. Is 10% correct accross the board? In not too familiar with cutting, but have seen a friend cut product with creatine and acetone. Yes scales were used to mix the two powders, but its hard to tell if that distrobution is exact once you spread it out and apply acetone.
2. If you hit a hotspot with something like am2201 it can be real bad, but im sure its a shit ton worse with a product multiple times stronger.
(Granted these are assumptions based on personal experience of watching while this process was administered to cocaine hcl.. which i refuse to take, so i cant say ive ever hit a hot spot)